出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/09/05 06:12:18」(JST)
| Systematic (IUPAC) name | |
|---|---|
|
Poly(4-vinylbenzenesulfonic acid)
|
|
| Clinical data | |
| Trade names | Sodium salt: Kayexalate, Kionex, Resonium A Calcium salt: Calcium Resonium, Sorbisterit, Resikali |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682108 |
| Pregnancy category |
|
| Routes of administration |
Oral, retention enema |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | None |
| Metabolism | None |
| Excretion | Faeces (100%) |
| Identifiers | |
| CAS Number | 28210-41-5 Y |
| ATC code | V03AE01 (WHO) |
| PubChem | CID 75905 |
| DrugBank | DB01344 Y |
| ChemSpider | None |
| KEGG | DG01160 |
| Chemical data | |
| Formula | [C8H7SO3−]n |
| (verify) | |
Polystyrene sulfonates are polymers derived from polystyrene but containing sulfonate functional groups. They are widely used to remove ions such as potassium, calcium and sodium from solutions in technical or medical applications.
Linear ionic polymers are generally water-soluble. Crosslinked materials (called resins) do not dissolve in water. These polymers are classified as polysalts and ionomers.[1]
Under the name tolevamer, a polystyrene sulfonate was investigated by Genzyme as a toxin binding agent for the treatment of Clostridium difficile associated diarrhoea (CDAD), but never marketed.
Polystyrene sulfonate (trade name Kayexalate and others) is usually supplied in the sodium and calcium form. It is used as a potassium binder in acute and chronic kidney disease for people with hyperkalaemia (abnormal high blood serum potassium levels).[2] It however is unclear if it works and there is concern about possible side effects when it is mixed with sorbitol.[3]
Polystyrene sulfonates are administered orally (with a meal) or rectally, by retention enema.[4]
The drug is contraindicated in patients with obstructive bowel disease and in newborn children with reduced gut motility.[5]
Intestinal disturbances are common, including loss of appetite, nausea, vomiting, and constipation. In rare cases, it has been associated with colonic necrosis.[6] Changes in electrolyte blood levels may occur such as hypermagnesemia, hypercalcemia, and hypokalemia.[7]
Polystyrene sulfonates can bind to various drugs and thus lower their absorption and effectiveness. Examples include lithium and thyroxine. Digitalis is more likely to cause side effects in the presence of hypokalemia, which can be caused by polystyrene sulfonate. Cases of intestinal necrosis have been reported when this polymer was combined with sorbitol.[5]
Polystyrene sulfonates release sodium or calcium ions in the gut (mainly in the large intestine) in exchange for free potassium ions, lowering the amount of potassium available for absorption into the blood and increasing the amount that is excreted via the feces. The effect is a reduction of potassium levels in the body.[5]
Tolevamer was designed to bind the enterotoxins rather than attack C. difficile directly. Since it has no antibiotic properties, it does not harm the gut flora. Early studies used the sodium salt, but it was soon replaced with the potassium sodium salt to prevent hypokalaemia which is often associated with diarrhoea.[8][9]
Polystyrene sulfonates are useful because of their ion exchange properties.[1]
Water softening is achieved by percolating hard water through a bed of sodium form of cross-linked polystyrene sulfonate. The hard ions such as calcium (Ca2+) and magnesium (Mg2+) adhere to the sulfonate groups, displacing sodium ions. The resulting solution of sodium ions is softened.
Sodium polystyrene sulfonate is used as a superplastifier in cement, as a dye improving agent for cotton, and as proton exchange membranes in fuel cell applications. In their acid form, the resin is used as a solid acid catalyst in organic synthesis.[10]
Polystyrene sulfonic acid has the idealized formula (CH2CHC6H4SO3H)n. The material is prepared by sulfonation of polystyrene:
Several methods exist for this conversion, which can lead to varying degree of sulfonation. Usually the polystyrene is crosslinked, which keeps the polymer from dissolving. Since the sulfonic acid group (SO3H) is strongly acidic, this polymer neutralizes bases. In this way, various salts of the polymer can be prepared, leading to sodium, calcium, and other salts:
These ion-containing polymers are called ionomers.
Double substitutions of the phenyl rings are known to occur, even with conversions well below 100%. Crosslinking reactions are also found, where condensation of two sulfonic acid groups yields a sulfonyl crosslink. On the other hand, the use of milder conditions such as acetyl sulfate leads to incomplete sulfonation. Recently, the atom transfer radical polymerization (ATRP) of protected styrenesulfonates has been reported,[11][12] leading to well defined linear polymers, as well as more complicated molecular architectures.[13]
In early 2008, a noninferiority study versus vancomycin or metronidazole found that about half of the patient in the tolevamer group did not complete the treatment, versus 25% in the vancomycin and 29% in the metronidazole groups.
CDAD recurrence in patients reaching clinical success was reduced significantly by tolevamer (6% recurrence rate), vancomycin (18%) and metronidazole (19%). However, the good result of tolevamer is partly due to the high drop-out rate in this group.
Since tolevamer did not reach its primary endpoint in this study, the development was halted.[14]
Drugs for treatment of hyperkalemia and hyperphosphatemia (V03AE)
|
|
|---|---|
| Potassium binders |
|
| Phosphate binders |
|
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
| リンク元 | 「ポリスチレンスルホン酸」「ポリスチレンスルホン酸カルシウム」「polystyrene sulfonate」 |
| 関連記事 | 「sulfonate」「polystyrene sulfonate」「calcium」「polystyrene」 |
・リスチレン